title: Droperidol for acute migraine headache.
abstract: The use of intramuscular droperidol to treat acute migraine headache has not been previously reported in the emergency medicine literature. It is a promising therapy for migraine. The authors performed a pilot review of all patients receiving droperidol for migraine in our emergency department (ED) to evaluate its efficacy. We used a retrospective case series, in a suburban ED with an annual patient census of 48,000. All patients with a discharge diagnosis of migraine headache who were treated with i.m. droperidol during a consecutive 5-month period in our ED were identified. All patients received droperidol 2.5 mg intramuscular. As per ED protocol, their clinical progress was closely followed and documented at 30 minutes after drug administration (t30). Demographic and clinical variables were recorded on a standardized, closed-question, data collection instrument. The primary outcome measurement was relief of symptoms at t30 to the point that the patient felt well enough to go home without further ED intervention (symptomatic relief). Thirty-seven patients were treated (84% female), with an ED diagnosis of acute migraine with droperidol during the study period. The mean age was 36 +/- 12 years. Analgesics had been used within 24 hours before ED presentation by 62% of patients. At t30, 30 (81%) patients had symptomatic relief, 2 (5%) felt partial relief but required rescue medication, and 5 (14%) had no relief of symptoms. Drowsiness (14%) and mild akathisia (8%) were the only adverse reactions observed following drug administration. Droperidol 2.5 mg intramuscular may be a safe and effective therapy for the ED management of acute migraine headache. Randomized, controlled trials are warranted to further validate the findings of this preliminary study.
authors.affiliation: Department of Emergency Medicine, Morristown Memorial Hospital, NJ 07962, USA.
authors.forename: P B
authors.initials: PB
authors.lastname: Richman
authors.forename: U
authors.initials: U
authors.lastname: Reischel
authors.forename: A
authors.initials: A
authors.lastname: Ostrow
authors.forename: C
authors.initials: C
authors.lastname: Irving
authors.forename: A
authors.initials: A
authors.lastname: Ritter
authors.forename: J
authors.initials: J
authors.lastname: Allegra
authors.forename: B
authors.initials: B
authors.lastname: Eskin
authors.forename: P
authors.initials: P
authors.lastname: Szucs
authors.forename: A H
authors.initials: AH
authors.lastname: Nashed
mesh_terms: D000208:Acute Disease; D000328:Adult; D017109:Akathisia, Drug-Induced / Q000209:etiology; D000700:Analgesics / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004329:Droperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007273:Injections, Intramuscular; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy*; D010865:Pilot Projects; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012894:Sleep Stages / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000700:Analgesics; D018492:Dopamine Antagonists; D004329:Droperidol